Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
AssigneeHavah Therapeutics Pty Ltd.
InventorStephen Nigel BIRRELL
Life of this patent
Estimating the term…
Loading patent…
AssigneeHavah Therapeutics Pty Ltd.
InventorStephen Nigel BIRRELL
Estimating the term…
The present disclosure is directed formulations, delivery systems and/or methods of use that have a novel a sustained release multi-phasic concentration pattern that may be used, among other things, for reducing mammographic breast density and/or breast stiffness in warm-blooded animals. For example, the formulation may comprise: the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor to a subject that provides a sustained release multi-phasic concentration pattern in the blood of the subject over time as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor and improves, among other things, breast tissue stabilization and/or increases of the levels of androgen receptor expression. The present disclosure is also directed to the use of an effective amount of an androgenic agent in combination with an effective amount of an aromatase inhibitor for the prophylaxis or treatment of autoimmune inflammatory mastitis (AIM) in a patient in 15 need thereof. Autoimmune inflammatory mastitis includes the conditions of idiopathic inflammatory macromastia, plasma cell mastitis, granulomatous mastitis.
1-31. (canceled)
A method for the prophylaxis or treatment of autoimmune inflammatory mastitis in a patient in need thereof, comprising administering to the patient i) an effective amount of an androgenic agent in combination with ii) an effective amount of an aromatase inhibitor.
(canceled)
(canceled)
(canceled)
51-57. (canceled)
Dependencies are inferred from the claim text.